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Abstract
Background: Clusterin (CLU) is an enigmatic molecule associated with various physiological
processes and disease states. Different modes of cellular stress lead to increased CLU levels, and
additionally numerous growth factors and cytokines affect the expression of the CLU gene. APC
and c-MYC, both intimately linked to the Wnt signaling pathway have previously been shown to
influence CLU levels, and we therefore investigated if changes in Wnt signaling activity in vitro could
regulate the expression of one, or more, of several CLU mRNA and protein variants.
Results: Over-expression of the cytoplasmic domain of E-cadherin tagged with GFP was used to
abrogate Wnt signaling activity in LS174T and HCT116 colon carcinoma cells. This fusion construct
sequestered signaling competent β-catenin whereby Wnt signaling was abrogated, and
consequently cytoplasmic CLU protein levels increased as demonstrated by immunofluorescence.
To determine which branch of the Wnt pathway was mediating the CLU response, we over-
expressed dominant negative (dn) TCF1 and TCF4 transcription factors in stably transfected
LS174T cells. We observed both intra- and extracellular levels of CLU protein to be induced by
dnTCF1 but not dnTCF4. Subsequent analysis of the expression levels of three CLU mRNA
variants by real time RT-PCR revealed only one CLU mRNA variant to be responsive to dnTCF1
over-expression. 5'-end RACE indicated that this CLU mRNA variant was shorter at the 5'-end
than previously reported, and accordingly the translated protein was predicted to be shorter at the
N-terminus and destined to the secretory pathway which fit our observations. Examination of the
immediate expression kinetics of CLU after dnTCF1 over-expression using real time RT-PCR
indicated that CLU might be a secondary Wnt target.
Conclusion: In conclusion, we have demonstrated that the Wnt signaling pathway specifically
regulates one out of three CLU mRNA variants via TCF1. This CLU transcript is shorter at the 5'
end than reported by the RefSeq database, and produces the intracellular 60 kDa CLU protein
isoform which is secreted as a ~80 kDa protein after post-translational processing.
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Background
The clusterin (CLU) protein was first discovered more
than 25 years ago in rat testis fluid because of its ability to
facilitate clustering of a variety of cell types in culture[1].
Since then, homologues of the broadly expressed CLU
gene have been identified in several species and CLU pro-
teins have been found in most mammalian body flu-
ids[2]. CLU is an enigmatic molecule, implicated in
diverse biological processes, and has additionally been
associated with opposing functions in regard to apoptosis.
Accumulating evidence from several studies suggests that
the pro- and antiapoptotic functions may be related to
nuclear and secreted protein isoforms, respectively[3].
The secreted form of CLU is a glycosylated protein of 70–
80 kDa that consists of two chains held together by five
disulfide bonds, and consequently it appears as a ~40 kDa
smear on immunoblots from reducing SDS-PAGE. Its
intracellular pre-curser form of 60 kDa may also exhibit
an antiapoptotic function[4]. The proapoptotic CLU vari-
ant is a 50–55 kDa protein which accumulates in the
nucleus of apoptotic cells[3]. How these different CLU
protein variants are produced from the CLU gene is poorly
understood, although it has been speculated that nuclear
CLU results from an alternative splice event skipping exon
2 from the main CLU transcript otherwise translated into
secreted CLU[5].
CLU is recognized as being a stress-inducible gene, thus
responding to a variety of general stress stimuli such as
oxidative stress, ionizing radiation and heatshock. In
addition, several cytokines and growth factors either pro-
mote or suppress CLU expression in vitro[2]. Numerous
functional cis-elements and trans-factors have been identi-
fied which are responsible for regulating CLU expression
under different conditions in vitro.  Trans-factors which
have been shown to interact with the CLU promoter, and
regulate its activity, include Egr-1[6], members from the
AP-1 complex[7], HSF1/2[8], Cdx1/2[9], and B-MYB[10].
Hence, many cis/trans-factors have been identified which
may be responsible for the complex tissue-specific control
of the gene. The complexity of CLU regulation is also illus-
trated by the observations that identical growth factors
may elicit different CLU responses depending on the cell
type of exposed cells, and whether cells are grown as
mono- or mixed cultures in vitro[2]. In contrast to the
avian CLU gene whose expression can be driven by two
alternative promoters[11], CLU expression in mammals
has traditionally been thought to be controlled by one
promoter only. However, several novel CLU mRNA vari-
ants have recently been identified in human colon and
prostate cells, and two of these transcripts were demon-
strated to be differentially regulated by androgens in pros-
tate cells[12,13]. Considering the recent discovery of these
CLU transcripts little is known about their biological rele-
vance and regulation, including whether transcription of
each mRNA species is initiated from the same promoter or
perhaps different promoters. Furthermore, it is also
unclear how they each relate to the different CLU isoforms
observed at the protein level. Investigating these issues is
important for understanding CLU regulation and func-
tion. Over-expression of oncogenes B-MYB and c-MYC,
has been reported to induce and repress CLU, respec-
tively[10,14]. Of note, c-MYC is recognized as being a tar-
get of the Wnt signaling pathway[15]. Another Wnt
component, APC, lead to elevated CLU levels when being
over-expressed in a null APC-/- human colon cancer cell
line[16]. Collectively, these studies made us speculate that
one, or more, of the CLU mRNA variants might be regu-
lated by Wnt signaling. Accordingly, we used a model sys-
tem based on human colon adenocarcinoma cells to
investigate whether CLU expression could be regulated by
changes in Wnt signaling. Indeed, we show that by abro-
gating the otherwise constitutively activated Wnt pathway
in these cells, CLU protein levels are up-regulated. Con-
comitantly, we observed increased levels of one out of
three CLU mRNA variants, previously identified in
colonic tissue. Induction of CLU is further demonstrated
to be mediated by the transcription factor, TCF1.
Results
Sequestration of β-catenin increases CLU protein levels in 
colon carcinoma cells
To determine if Clusterin protein levels are affected by
alterations in Wnt signaling activity, we transiently trans-
fected the colon carcinoma cell lines, LS174T and
HCT116, with a fusion construct consisting of GFP fused
to the cytoplasmic domain of E-cadherin. The encoded
fusion protein efficiently sequesters signaling competent
β-catenin, thus abrogating the Wnt signaling pathway
which is otherwise constitutively activated in these cell
lines due to activating mutations in β-catenin.
To validate that the fusion protein indeed sequestered β-
catenin, we first performed immunofluorescence using an
anti-β-catenin antibody. As expected, over-expression of
the GFP-cyt-E-cadherin construct resulted in a strong
decrease of nuclear β-catenin staining in both cell lines,
which instead co-localized with the GFP-cyt-E-cadherin
fusion in a perinuclear pattern (white arrow heads; Fig.
1A). When staining transfected cells using an anti-CLU
antibody, CLU was found to be predominantly up-regu-
lated in GFP-cyt-E-cadherin transfected cells relative to
GFP-transfected cells (and non-transfected cells), and
exhibited a cytoplasmic localization (yellow arrow heads;
Fig. 1A, and Additional file 1). In GFP-transfected and
non-transfected cells, the CLU signal was close to back-
ground and CLU staining, if any, was confined to the cyto-
plasm. In agreement with these results western blotting
demonstrated that CLU was up-regulated in LS174T cells
transiently transfected with GFP-cyt-E-cadherin relative toJournal of Molecular Signaling 2007, 2:6 http://www.jmolecularsignaling.com/content/2/1/6
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the GFP control transfectants (Fig. 1B). To make sure that
the GFP-cyt-E-cadherin affected the expression levels of
known Wnt target genes western blotting was used to
detect changes in the levels of the well-known Wnt target,
c-MYC. In accordance with c-MYC being positively regu-
lated by Wnt signaling[15], c-MYC protein levels were
reduced upon expression of GFP-cyt-E-cadherin confirm-
ing that the GFP-cyt-E-cadherin construct had a functional
impact on the expression of Wnt target genes. The up-reg-
ulation of CLU (and down-regulation of c-MYC) detected
by western blotting was modest, which is possibly attrib-
utable to the combination of a moderate transfection effi-
ciency (~30%) and that only a subpopulation of
transfected cells up-regulate CLU (see Additional file 1).
Altogether the data showed that inhibition of Wnt signal-
ing by sequestration of β-catenin led to increased CLU lev-
els.
Wnt regulation of CLU is mediated by TCF1
The outcome of the Wnt signaling pathway is ultimately
determined by its most downstream effectors; members
from the T-cell factor (TCF)/lymphoid enhancer factor
(LEF) family. To elucidate which TCF-branch of the Wnt
signaling pathway was responsibly for the observed
changes in CLU protein levels, we used LS174T cells stably
transfected with either doxycycline-inducible dominant
negative (dn) TCF1 or TCF4 factors. As a first step we eval-
uated these model systems. Western blotting confirmed
that both dnTCF1 and dnTCF4 proteins were strongly
induced upon addition of doxycycline (Fig. 2C). In agree-
ment with previous reports, expression of either dnTCF
resultated in a strong decrease in cell growth rate as veri-
fied by two independent proliferation assays (Fig. 2A,B).
Having confirmed the induction of exogenous dnTCFs
and the accompanying growth inhibitory phenotype, we
also wanted to make sure that the expression levels of
transcriptional Wnt targets were affected. Accordingly, we
used western blotting to detect changes in the levels of the
Wnt target, c-MYC, which were shown to be drastically
reduced upon expression of either dnTCF (Fig. 2D). Col-
lectively, these observations suggested the stably trans-
fected LS174T cell lines to be a reliable Wnt model system.
Western blotting was used to detect changes in CLU pro-
tein levels upon expression of either dnTCF. Interestingly,
only over-expression of dnTCF1, but not dnTCF4, lead to
increased CLU protein levels (Fig. 3A). No increase in
CLU protein levels was evident in control cells not stably
transfected with dnTCF-vectors but exposed to doxycy-
cline. To exclude the possibility that loss of integrity of the
CLU locus was the reason why CLU was not induced after
dnTCF4 over-expression, we sequenced the coding
regions of the CLU gene in the stably transfected LS174T
dnTCF4 cell line as well as the dnTCF1 and control cell
Sequestration of β-catenin by GFP-tagged E-cadherin lead to  up-regulation of CLU levels in colon carcinoma cells Figure 1
Sequestration of β-catenin by GFP-tagged E-cadherin 
lead to up-regulation of CLU levels in colon carci-
noma cells. Changes in CLU protein levels were investi-
gated in response to over-expression of GFP tagged E-
cadherin and GFP as control. (A) Immunofluorescence was 
used to show the effects of transient over-expression of GFP 
tagged E-cadherin, which binds β-catenin, in LS174T and 
HCT116 colon carcinoma cell lines. In the left panel it is 
shown that the GFP-cyt-E-cadherin fusion protein efficiently 
sequesters β-catenin from the nucleus whereupon Wnt sign-
aling is abrogated. In transfected cells (white arrow heads) β-
catenin has a perinuclear localization contrasting untrans-
fected cells (white arrows) where it is uniformly distributed. 
Shown in the right panel is the up-regulation of cytoplasmic 
CLU protein which follows the abrogation of Wnt signaling 
induced by the GFP-cyt-E-cadherin fusion protein. CLU is up-
regulated in GFP-cyt-E-cadherin transfected cells (yellow 
arrow heads) but not in untransfected cells nor in cells trans-
fected with GFP alone. (B) Western blot with cell lysates 
from LS174T cells 24 hr after transient transfection with 
GFP-cyt-E-cadherin and GFP as a control. β-actin was used as 
a loading control. CLU protein levels are up-regulated and c-
MYC protein levels are down-regulated as a consequence of 
over-expressing GFP-cyt-E-cadherin but not GFP alone. WB: 
western blot, ab: Antibody.
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lines. No mutations were identified, only a silent C/T SNP
in exon 5 of all three LS174T derived cell lines (data not
shown), thus strengthening the conclusion that CLU was
exclusively regulated by TCF1. The induced CLU protein
species appeared as a distinct band of 60 kDa and a faint
band of ~40 kDa (Fig. 3A). CLU exists as different protein
isoforms which are reported to localize differently both
intra- and extracellularly. The 60 kDa CLU isoform has
consistently been reported to exhibit a cytoplasmic local-
ization pattern which is exactly what we observed in our
transient transfection experiments using GFP-cyt-E-cad-
herin (Fig. 1A). To confirm that CLU exhibited a similar
subcellular distribution in dnTCF1 over-expressing cells,
we performed immunofluorescence using an anti-CLU
antibody. In agreement with our previous results the
induced CLU proteins were found to be localized in the
cytoplasm (Fig. 3B).
Wnt signaling regulates the secreted CLU protein isoform
The 60 kDa CLU isoform can be converted to a ~80 kDa
heterodimer isoform through glycosylation and proteo-
lytic cleavage[17]. Consequently, this mature CLU iso-
form appears as a ~40 kDa smear on reducing SDS-PAGE
immunoblots[2,3]. In contrast to the cytoplasmic 60 kDa
form, this latter CLU protein species is secreted by the cells
and can thus be found in the extracellular milieu. How-
ever, under certain stress conditions, CLU can be diverted
from its normal secretory pathway and reach the cytosol
by means of retrotranslocatio[18]. To investigate whether
the CLU species induced by abrogated Wnt signaling was
indeed secreted, western blotting was used to detect
secreted CLU proteins in the culture medium at various
time points after induction of dnTCF1. Our analysis
revealed that CLU accumulated in the culture medium
after induction of dnTCF1 (Fig. 3C). This was not the case
Intra- and extracellular CLU protein levels are increased spe- cifically in response to dnTCF1 over-expression Figure 3
>Intra- and extracellular CLU protein levels are 
increased specifically in response to dnTCF1 over-
expression. Changes in CLU protein levels were investi-
gated in response to over-expression of dnTCF1 and 
dnTCF4 in stably transfected LS174T derived cell lines. (A) 
Western blot with cell lysates from LS174T derived cell lines 
0, 12, and 24 hr after induction. β-actin was used as a loading 
control. CLU protein levels are up-regulated after induction 
of dnTCF1, but not dnTCF4, and appear as a strong 60 kDa 
band and a faint ~40 kDa band. (B) Immunofluorescence in 
LS174T dnTCF1 cells, fixed 24 hr after either induction 
(+dox) or no induction (-dox). Intracellular CLU levels are 
up-regulated in response to induction of dnTCF1. The sub-
cellular localization of up-regulated CLU is mainly cytoplas-
mic (white arrows). No (primary) antibody control is also 
shown. (C) Over-expression of dnTCF1 in LS174T cells also 
led to increased levels of extracellular CLU as demonstrated 
by western blot with acetone-precipitated total proteins 
from culture supernatant 0, 25, and 48 hr after induction. 
CLU appears as a ~40 kDa smear which is consistent with 
the secreted form of CLU being a cleaved glycosylated pro-
tein that consists of two chains of similar molecular weight, 
held together by several disulfide bonds.
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Evaluation of dnTCF-Wnt-model system: Expression of  exogenous gene products and phenotypic change Figure 2
Evaluation of dnTCF-Wnt-model system: Expression 
of exogenous gene products and phenotypic change. 
Doxycycline-inducible dominant negative (dn) versions of 
TCF1 and TCF4 factors, the effectors of the Wnt pathway, 
were over-expressed in stably transfected LS174T derived 
cell lines. (A) Proliferation was halted in LS174T derived cell 
lines after induction of both dnTCFs. This was visualised by 
methyl violet staining of cell cultures after 5 days of induc-
tion. (B) Similar results were obtained by manually counting 
cells in a haemocytometer after cells had been cultured in 
the presence (+) or absence (-) of induction for 4 days. Data 
are presented as the mean ± standard deviation from 3 sepa-
rate experiments. (C) Induction of exogenous gene prod-
ucts, dnTCFs, was detected by western blot with cell lysates 
from LS174T derived cell lines 0, 12, and 24 hr after induc-
tion. Control cells are LS174T cells without any dnTCF 
expression vector. (D) Both dnTCF1 and dnTCF4 abrogate 
β-catenin/TCF driven transcription of the Wnt-target gene, 
c-MYC, as analyzed by western blot with cell lysates from 
LS174T derived cell lines 0 and 12 hr after induction.
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for control cells. This implies that the up-regulation of the
intracellular pre-curser form of CLU, 60 kDa, is followed
by maturation and secretion of the mature CLU form.
Accordingly, secreted CLU appeared as a ~40 kDa smear
on the immunoblots. Not much, if any, of the ~40 kDa
smear band was observed to accumulate intracellularly
(Fig. 3A). This may be explained by a high secretion rate
of CLU, which would keep the intracellular pool of
mature CLU protein low, and has been observed to occur
rapidly in human liver carcinoma cells (HepG2) with
half-times of 30–35 min[17,19].
dnTCF over-expression increase cell death rate in LS174T 
cells
Increased CLU levels have often been associated with
necrotic tissues, and apoptotic cells in particular, although
it is still unclear whether CLU is a cause or consequence of
dying cells[2,3]. Abrogation of Wnt signaling in colon car-
cinoma cells is known to result in a robust growth arrest
and may further enhance cell death rate[16,20]. To inves-
tigate whether the observed changes of CLU expression
was simply a secondary effect of increased cell death rate
we used two independent cell death assays to quantify
dying cells. We observed no increases in cell death rate
within 24 hr after induction of dnTCF1 in LS174T cells
(Fig. 4A,B) which is in agreement with a previous study
that obtained similar results within 20 hr of induc-
tion[20]. However, at 48 hr after induction a significant
increase in cell death rate was observed (p < 0.005; Fig.
4A,B). Accordingly, a reduction in cell viability was also
observed after 48 hr using a MTT assay which measured
cells ability to metabolically convert the MTT substrate
(Fig. 4C). Considering CLU is up-regulated already after
12 hr (Fig. 3A), and increased cell death rate is not
observed until 48 hr after induction (Fig. 4A,B), it does
not appear as if CLU is a secondary effect of cell death.
Accordingly, the apoptosis-associated nuclear 50–55 kDa
CLU protein variant (nCLU) was apparently not induced
(Fig. 3A,B) which would have been expected had CLU
been induced by dying cells.
Characterization of the 5' end of the NM_001831.2 mRNA 
variant
Previously we have demonstrated that three different CLU
mRNA variants are expressed in cancerous and normal
colonic epithelial cells[12]. One of these variants corre-
sponded to the NCBI RefSeq sequence NM_001831.2.
Curiously, a closer inspection of the first exon in the
NM_001831.2 transcript revealed the sequence to contain
the putative TATA-box sequence previously reported for
this transcript[21]. This was unexpected considering the
transcription machinery involving RNA polymerase II
usually initiates transcription downstream from the
TATA-box which is centered between positions -30 and -
100. By consulting the CLU unigene cluster (Hs. 436657)
through the UCSC genome browser[22] only one full-
length cDNA out of 90 supported the extreme 5' end cov-
ering the TATA-box sequence. Additionally, we were una-
ble to generate RT-products when placing the sense
primer upstream of the TATA-box sequence. Collectively,
these observations made us question whether the
NM_001831.2 mRNA sequence obtained from the RefSeq
database was valid. Specifically, we suspected the tran-
script to be shorter at the 5' end and thus not contain the
TATA-box motif. To resolve this issue, we performed 5'
rapid amplification of cDNA ends (RACE) using a colon
adenocarcinoma adaptor-ligated cDNA library. The 5' end
Over-expression of dnTCF1 lead to reduced viability and  increased cell death rate in LS174T cells Figure 4
Over-expression of dnTCF1 lead to reduced viability 
and increased cell death rate in LS174T cells. Over-
expression of dnTCF1 significantly increases the rate of cell 
death in LS174T cells 48 hr after induction (p < 0.005, stu-
dent's t-test). This was determined using two cell death 
assays based on either trypan blue dye or DNA-intercalating 
dyes, propidium iodide (PI) and hoechst 342 (HST). LS174T 
control and dnTCF1 cell lines were cultured in the presence 
of induction. After 24 hr and 48 hr, floating and attached cells 
were stained with the respective dyes. Data from both assays 
are presented as the mean ± standard deviation from 3 sepa-
rate experiments. (A) PI/HST assay: Cells were stained with 
PI (stains apoptotic/necrotic cells) and HST (stains viable 
cells). Percentage of PI stained cells relative to total cell 
number reflect the extent of cell death. (B) Trypan blue dye 
exclusion assay: Cells were stained with the trypan blue dye. 
Percentage of trypan blue stained cells (stains dead cells) rel-
ative to total cell number reflect extent of cell death. (C) 
MTT viability assay: The cells' capability to metabollically con-
vert the MTT substrate was quantified, 48 hr after either 
induction (+dox) or no induction (-dox), by solubilizing MTT 
formazan crystals and performing spectrophotometry at 540 
nm. Cell viability, which is proportional to the absorbance at 
540 nm, decreases in dnTCF1 over-expressing LS174T cells 
relative to control cells.
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of the transcript was determined by sequencing three
cloned PCR fragments. Neither cloned fragment sup-
ported the extreme 5' end of the NM_001831.2 sequence
overlapping the TATA-box (Fig. 6). In conclusion, it
appears as if the NM_001831.2 transcript is not expressed
in colonic cells, rather a similar but shorter transcript is
expressed (hereinafter referred to as CLU34). Importantly,
the proteins predicted from the two sequences differ (see
below).
In silico analysis of CLU mRNA variants
In addition to CLU34, two other variants, referred to as
CLU35 and CLU36, have also been identified in colon tis-
sue [12]. These transcripts all consist of 9 exons and only
differ in regard to their first exon (Fig. 5B). Which one of
these transcripts is responsible for the individual CLU
protein isoforms is at present still unclear.
Using the largest open reading frame (ORF), we predicted
the CLU34 and CLU35 mRNA isoforms to produce iden-
tical proteins of 449 amino acids (AAs). In contrast, the
CLU36 transcript produces a hypothetical protein of 460
AAs. The subcellular localization of these proteins was
predicted[23] to be nuclear in the case of CLU36, whereas
the proteins produced from the CLU34/35 transcripts
were secreted. Of notice, had CLU34 shared its 5' end with
the NM_001831.2 RefSeq variant then a predicted nuclear
protein of 501 AAs would be produced with expected dis-
tinct biological functions.
To summarize, the in silico predictions suggested that
CLU34 and CLU35 might, individually or in combina-
tion, be responsible for the generation of cytoplasmic and
secreted CLU proteins.
TCF1-mediated Wnt signaling specifically regulates the 
CLU34 mRNA variant
To determine if any of these CLU mRNA species was
responsive to alterations in Wnt signaling, in which case
they would be likely templates for the production of the
60 kDa/~40 kDa CLU proteins, we quantified the relative
expression levels of each mRNA variant by real time RT-
PCR at various time points after induction of dnTCF1.
Neither the CLU35 nor the CLU36 mRNA variants were
responsive to alterations in Wnt signaling. In fact, they
were expressed at very low levels, often below the detec-
tion limit of the real time RT-PCR assay (data not shown).
In contrast, CLU34 mRNA baseline expression levels were
higher, and intriguingly, this particular mRNA variant was
strongly up-regulated as a response to over-expression of
dnTCF1 (Fig. 7). These observations suggested CLU34
mRNA to be the template for the production of the the 60
kDa/~40 kDa CLU proteins.
To verify that these transcriptional responses were specific
for dnTCF1, and not dnTCF4, we used real time RT-PCR
to measure the expression levels of each CLU mRNA vari-
ant in response to dnTCF4 over-expression. As expected,
none of the CLU mRNA variants responded to the induc-
tion of dnTCF4 (Fig. 7), and in agreement with our previ-
ous observations both CLU35 and CLU36 were expressed
at very low levels, often below the detection limit of the
Characterization of the 5'-UTR of the CLU34 transcript by  5'-end RACE and RT-PCR Figure 6
Characterization of the 5'-UTR of the CLU34 tran-
script by 5'-end RACE and RT-PCR. A colon adenocar-
cinoma cDNA library was used for 5'-end rapid amplification 
of cDNA ends (RACE) to determine the sequence of the 
extreme 5'-end of CLU34 mRNA. None of the three cloned 
5'-end RACE fragments or the RT PCR analysis supported 
the most 5' extreme end of the CLU34 transcript containing 
the putative TATA-box as suggested by the RefSeq database. 
The 5'-end RACE results were consistent with results from 
RT-PCR reactions which only yielded an amplification prod-
uct if the sense primer was placed downstream of the puta-
tive TATA-box.
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Genomic structure of CLU locus and exon-composition of  CLU mRNA variants expressed in colonic cells Figure 5
Genomic structure of CLU locus and exon-composi-
tion of CLU mRNA variants expressed in colonic 
cells. (A) Diagram depicts the genomic location of all CLU 
exons on chromosome 8 and potential TCF-binding sites 
(red arrows) predicted by the MatInspector software. (B) 
Exonic structure of CLU mRNA variants.
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real time RT-PCR assay (data not shown). Thus, CLU34 is
specifically regulated by TCF1 in LS174T cells. In addi-
tion, over-expression of both dnTCF1 and dnTCF4 lead to
a marked reduction of c-MYC mRNA levels which is con-
sistent with c-MYC also being down-regulated at the pro-
tein level (Fig. 2D). Also, in agreement with previous
reports, p21CIP1/WAF1 mRNA levels increased as a conse-
quence of abrogated Wnt signaling by either dnTCF[20].
To investigate whether the extremely low expression levels
of CLU35 and CLU36 were a characteristic unique to our
model system, we screened a large panel of cell lines for
baseline expression levels of these transcripts. Besides a
variety of colon carcinoma cell lines, we also included a
number of prostate carcinoma cell lines in our analysis
since CLU has been reported to be up-regulated in this
cancer type[24,25]. In all 21 cell lines investigated, includ-
ing LS174T and HCT116, both CLU35 and CLU36 were
expressed at very low levels (see Additional file 2). In sev-
eral cell lines the transcripts were expressed below the
detection limit of the real time RT-PCR assay, and their
expression levels did not correlate with that of CLU34
which was expressed at varying levels across the entire
panel of cell lines (see Additional file 2). It therefore
appears as if the expression of the CLU35 and CLU36
transcripts are regulated by a promoter different from the
promoter controlling CLU34 expression, and that the
former is only minimally activated and may require spe-
cific signals such as androgens to get stimulated[13]. This
notion fits the observation that CLU35 can be specifically
up-regulated by androgens and that the responsive ele-
ments are located within the first 1200 bp of the CLU35
transcriptional initiation site[13]. This genomic region is
located approximately 2000 bp downstream from the
CLU34 promoter/initiation site (Fig. 5).
Expression kinetics of CLU34 in response to over-
expression of dnTCF1
While the expression of direct Wnt target genes is activated
by binding of TCF transcription factors to specific
sequence motifs in their promoters, the expression of
indirect target genes are regulated via transcription regula-
tors, which are targets of the Wnt pathway. For example,
the direct Wnt target gene c-MYC, represses the expression
of the indirect target p21CIP1/WAF1 by binding to the tran-
scriptional activator MIZ1 at the p21CIP1/WAF1  pro-
moter[20].
To get an indication of whether CLU was a direct or indi-
rect Wnt target, we searched the genomic DNA sequences
upstream of each unique CLU exon 1 for TCF binding
motives as these would be a prerequisite for direct regula-
tion of CLU by the Wnt pathway. Our analysis using the
MatInspector software[26] revealed a cluster of four
potential TCF binding sites upstream of exon 1a (CLU34).
Two additional potential TCF binding sites were localized
downstream from exon 1a in the DNA region spanning
exon 1a and exon 1c (Fig. 5A).
We next investigated the immediate expression kinetics of
CLU by measuring both CLU protein and mRNA levels at
Alterations of CLU, p21, and c-MYC mRNA levels after  induction of dnTCFs in LS174T cells Figure 7
Alterations of CLU, p21, and c-MYC mRNA levels 
after induction of dnTCFs in LS174T cells. The expres-
sion levels of various transcripts were monitored by real 
time RT-PCR after induction of dnTCFs in LS174T derived 
cell lines. Expression levels were normalized to the Ubiquitin 
C (UBC) transcript. The CLU34 mRNA variant is specifically 
up-regulated in response to dnTCF1 over-expression in 
LS174T cells. Data are presented as the mean ± standard 
deviation from 2 separate experiments with each experiment 
consisting of the mean value of 3 independent determina-
tions. c-MYC mRNA levels decrease, whereas p21CIP1/WAF1 
mRNA levels increase after induction of both dnTCFs.
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several time points within a 12 hr period after induction
of dnTCF1. We rationalized that the earlier a rise in CLU
levels could be demonstrated, the more likely it was that
CLU was directly regulated by Wnt signaling via TCF1.
Western blotting showed that dnTCF1 proteins could be
detected as early as 3 hr after addition of doxycycline (Fig.
8A). CLU levels, however, did not increase until 12 hr
after addition of doxycycline. In comparison, the direct
Wnt target, c-MYC, was down-regulated already after 6 hr.
Expression kinetics at the transcriptional level for both
CLU and c-MYC were highly similar to that seen at the
protein level (Fig. 8B). These observations suggested that
CLU might be an indirect target of Wnt signaling,
although it cannot be ruled out that (dn)TCF1s do bind
directly to the CLU promoter but secondary changes are
required before CLU can be induced.
We used real time RT-PCR to see if the transcriptional
response of the secondary Wnt target, p21CIP1/WAF1,
matched that of CLU[20]. This was indeed the case as
p21CIP1/WAF1 mRNA levels did not increase markedly until
12 hr after addition of doxycycline (Fig. 8B). In conclu-
sion, these data points towards CLU as being a secondary
target of the Wnt signaling branch mediated by TCF1
although the specific trans-factors responsible for CLU
induction remain to be experimentally identified in future
studies.
Discussion
Here, we demonstrate that abrogation of the Wnt signal-
ing pathway in colon carcinoma cells lead to up-regula-
tion of CLU. By further dissecting the molecular signaling
cascade responsible for increased CLU levels, we find that
changes in CLU expression are specifically controlled by
the branch of the Wnt pathway mediated by the transcrip-
tion factor TCF1.
Our finding, that CLU expression can be regulated by the
Wnt signaling pathway, add to the plethora of stimuli
which can regulate CLU levels. The CLU promoter has
already been shown to be responsive to a variety of exter-
nal stress-inducing agents such as oxidative stress, ioniz-
ing radiation, heat shock, and chemotherapeutics[2]. In
addition several types of growth factors including TGF-β,
NGF, EGF, PDGF, βFGF, and interleukin-1,-2 and -6 have
been demonstrated to influence CLU expression in cul-
tured cells[2]. Although some of these signals may ulti-
mately converge on identical downstream effectors
directly responsible for regulating CLU promoter activity,
several unique trans- and cis-factors have been demon-
strated to influence CLU levels[2,3]. Thus, CLU expression
can be modulated by many factors and their impact on
CLU levels may in some cases be context dependent. For
example, TGF-β and EGF treatment elevate CLU levels in
some cell types whereas the very same growth factors sup-
press CLU expression in others[2]. Also, interleukin-6
induced CLU expression in hepatoma cells (HepG2)
whereas CLU was down-regulated in rat glial cultures
exposed to the same cytokine[27,28].
The Wnt signaling pathway is known to be involved in the
development of colorectal cancer and is also of major
importance in colon physiology[29]. In particular, this
pathway controls the maintenance of colon tissue archi-
tecture by controlling epithelial cell behaviour in the
crypts of Lieberkühn. The pathway is activated in epithe-
lial cells at the crypt bottom and decreases in a gradient
toward the crypt top. In colonic epithelial cells, it may
therefore be expected that CLU is expressed in an inverse
pattern to that of Wnt signaling. This, however, does not
seem to be the case in the adult human colon as it has pre-
viously been reported that CLU only stains a small frac-
tion of scattered colonic epithelial cells with
neuroendocrine differentiation[12]. In this tissue it there-
fore appears as if the Wnt pathway is not the dominant
force controlling CLU expression. Rather, CLU expression
Expression kinetics of CLU mRNA and protein levels after  induction of dnTCF1 in LS174T cells Figure 8
Expression kinetics of CLU mRNA and protein levels 
after induction of dnTCF1 in LS174T cells. Expression 
kinetics of CLU mRNA and protein levels were studied 0, 3, 
6, and 12 hr after induction of dnTCF1 in LS714T cells. c-
MYC and p21CIP1/WAF1 mRNA levels were also monitored. 
(A) Western blot with cell lysates from LS174T cells 0, 3, 6, 
and 12 hr after induction. CLU protein levels do not increase 
until 12 hr after induction. Exogenous dnTCF1 proteins are 
induced as early as 3 hr after induction, and c-MYC protein 
levels decrease in parallel. (B) Real time RT-PCR shows that 
CLU34 and p21CIP1/WAF1 mRNA levels do not increase until 
12 hr after induction. c-MYC mRNA levels decrease 6 hr 
after induction. Data are presented as the mean ± standard 
deviation from 2 separate experiments with each experiment 
consisting of the mean value of 3 independent determina-
tions.
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is likely the result of a complicated interplay between var-
ious pathways. The notion that the complexity of CLU reg-
ulation in vivo is not always being fully recapitulated by in
vitro  model systems, was also recently emphasized by
Patel et. al who unexpectedly observed decreased CLU lev-
els with rat donor age in glial cultures, despite CLU in vivo
shows an opposite adult age trend: CLU expression
increases during aging in select brain regions and in neu-
rodegenerative disorders[27]. Although Wnt signaling
may not be the primary regulator of CLU expression in
human colonic epithelial cells, other studies indicate that
this might be the case in epithelia of the murine intestine.
Lars E. French and colleagues used in situ hybridization
(ISH) to investigate CLU expression during murine
embryogenesis, and found CLU to be weakly expressed in
dividing epithelial cells at the base of the villi in the small
intestine but strongly expressed in more differentiated
cells that line the rest of the villus[30]. Similarly, Suh E.
and colleagues used immunohistochemistry (IHC) to
show that epithelia of the developing murine intestine
was positive for CLU protein staining, and exhibited a gra-
dient of activity with higher expression in the villus com-
partment than in the crypts[9]. At least in the developing
murine small intestine, it may therefore be that Wnt sign-
aling contributes to modulate CLU expression in epithe-
lial cells.
Although we identified which TCF factor was responsible
for CLU up-regulation, namely TCF1, it remains to be
demonstrated whether TCF1, or other downstream effec-
tors, bind directly to the CLU promoter and regulate its
activity. A previous study reported the Wnt target, c-MYC,
to repress CLU expression in murine colonocytes
although no direct interaction between c-MYC and the
CLU promoter was demonstrated[14]. In agreement with
these observations we observed a decrease in c-MYC levels
before CLU was induced upon over-expression of dnTCF1
in LS174T cells. However, considering that c-MYC levels
also dropped when we over-expressed dnTCF4 and CLU
levels remained unchanged, we do not believe c-MYC to
regulate CLU levels in our model system. Notably, other
investigators found no changes in CLU levels in murine
fibroblast cells stably transfected with a c-MYC construct
compared to mock transfected cells[31]. Therefore, other
factors might be more likely to regulate CLU in our model
system, possibly, AP-1 or Egr-1 transcription factors which
can bind directly to the CLU promoter[6,7] and have been
demonstrated to be suppressed by Wnt signaling[32].
It has become clear that the CLU gene encode several
mRNA variants. At least three CLU mRNA variants are
expressed in colon tissue, CLU34, CLU35, and CLU36. It
has previously been reported that only one of these vari-
ants, CLU35, was down-regulated in human colorectal
tumors samples compared to normal tissue indicating
that the CLU mRNA variants may be differentially regu-
lated[12]. This view was supported by a recent study by
Cochrane et al. who used real time PCR to demonstrate
that two CLU transcripts could be differentially regulated
in prostate cells by androgens[13]. Interestingly, our
results indicate that the Wnt signaling pathway, via TCF1,
specifically regulate the expression levels of CLU34. Our
5'-end RACE results indicate that the NM_001831.2
sequence is not present in colon carcinoma cells and this
observation is further supported by the failure to detect
the full NM_001831.2 sequence by RT-PCR in normal
and cancerous colon tissue samples. Instead, both RT-
PCR[12] and real time PCR can successfully detect a tran-
script, CLU34, which is shorter at the 5'-end and matches
the most predominant CLU mRNA isoform previously
reported[21,2]. This shorter sequence has implications for
the nature of the predicted protein because the ATG of the
RefSeq NM_001831.2 exon 1 is not part of the CLU34
transcript and consequently the ORF of the predicted pro-
tein starts in exon 2. Hence identical proteins are pre-
dicted from the CLU35 and CLU34 transcripts.
Importantly, this common protein is predicted to be
secreted which fits exactly with what we find in our model
system, as concomitantly with the induction of CLU34
mRNA an abrupt increase in cytoplasmic and secreted
CLU protein species is observed. Thus, the CLU34 mRNA
species apparently produce these protein variants.
The existence of two human CLU transcripts (CLU34/35)
probably encoding identical CLU proteins is paralleled by
previous findings in quail which demonstrated that two
CLU transcripts with different, mutually exclusive, non-
coding 5' exons can be produced from the avian gene.
However, whereas the avian CLU transcripts are produced
from two promoters often being co-regulated as suggested
by correlating expression levels of the two CLU transcripts
in tissue samples from a variety of organs[11], the human
CLU transcripts are clearly differentially regulated.
Conclusion
In conclusion, we have demonstrated that the Wnt signal-
ing pathway specifically regulates one out of three CLU
mRNA variants via TCF1. This CLU transcript is shorter at
the 5' end than reported by the RefSeq database, and pro-
duces the intracellular 60 kDa CLU protein isoform which
is secreted as a ~80 kDa protein after post-translational
processing.
Methods
Cell culture and transient transfections
LS174T derived and HCT116 cell lines were maintained in
RPMI 1640 + 25 mM hepes medium (Invitrogen/Gibco,
Carlsbad, CA, USA) and McCoy's 5A medium, respec-
tively. Each medium was supplemented with 5% foetalJournal of Molecular Signaling 2007, 2:6 http://www.jmolecularsignaling.com/content/2/1/6
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bovine serum (Invitrogen/Gibco) and 1% penicillin-
streptomycin (Invitrogen/Gibco).
The inducible LS174T derived cell lines have previously
been described[20] and were a kind gift from Dr. Hans
Clevers (The Hubrecht Laboratory, The Netherlands).
Induction was performed using 1 μg/ml doxycycline (Inv-
itrogen). Selection was performed on all the LS174T
derived cell lines using 10 μg/ml blasticidin (Invitrogen).
500 μg/ml zeocin (Invitrogen) was additionally used for
inducible LS174T dnTCF1/4 cell lines. All cell lines were
free of mycoplasma contamination as verified by the
MycoSensor™ PCR assay kit (Stratagene, La Jolla, CA,
USA) according to manufacturers instructions.
For transient transfection experiments involving immun-
ofluorescence, LS174T and HCT116 colon carcinoma cell
lines were transfected using Fugene 6 (Roche Applied Sci-
ence, Hvidovre, DK), according to the instructions of the
supplier. For transient transfection experiments involving
western blotting, LS174T cells were resuspended at 2 × 106
cells/transfection in Amaxa buffer (solution V) and elec-
troporated (program T30) with 10 μg of DNA per con-
struct as per manufacturer's protocol (Amaxa, Cologne,
Germany) and grown in 6-well plates. The GFP-cyt-E-cad-
herin plasmid was a kind gift from Dr. Philippe Blache
(Institut de Génétique Humaine, Centre National de la
Recherche Scientifique, France) and has previously been
described[33]. The GFP control plasmid, kindly provided
by ph.d Sanne Harder Olesen, was a pcDNA3.1 vector har-
boring the EGFP gene excised from the pEGFP-N1 vector
(Clontech).
Cell death assays
Two cell death assays, based on either trypan blue or pro-
pidium iodide (PI; Invitrogen) and hoechst 342 (HST;
Invitrogen), were used to assess cell death rate in LS174T
dnTCF1 and control cell lines 24 and 48 hr after induc-
tion. In brief, preattached cells were induced, and total
number of cells (floating and attached) were pelleted.
Cells were resuspended in either trypan blue solution
(Sigma-Aldrich A/S, Copenhagen, Denmark) or a PBS
solution containing DNA intercalating dyes, PI (10 μg/
ml) and HST (20 μg/ml), and aliquots were transferred to
a haemocytometer. For the trypan blue dye exclusion
assay, cells were observed under a light microscope, and
the extent of cell death was calculated as the percentage of
stained cells (apoptotic and/or necrotic) relative to total
cell number. For the PI/HST assay, images of stained
nuclei were captured using a camera with appropriate fil-
ters mounted on a conventional fluorescence microscope.
Viable cells were identified by intact nuclei with blue HST
fluorescence and necrotic/apoptotic cells (permeable to
PI) were identified by red PI fluorescence. To define a
fixed area, accompanying white light (phase) pictures
revealing the haemocytometer grid were layered on top of
the fluorescence pictures in Adobe Photoshop software.
An unpaired student's t-test was used to determine signif-
icant differences. Both assays were performed in biologi-
cal triplicates.
Proliferation and viability assays
Proliferation rate of uninduced and induced LS174T
derived cell lines were determined qualitatively by stain-
ing cultured cells with methyl violet (Bie & Berntsen,
Rødovre, DK) after 5 days and quantitatively by manually
counting attached cells in a haemocytometer after 4 days.
Both assays were done in biological triplicates. Images of
cells stained by methyl violet were acquired using a regu-
lar flatbed scanner after washing cells twice in PBS.
Cell viability was assessed using the Cell Proliferation Kit
I (MTT) from Sigma-Aldrich according to manufacturers
instructions. LS174T dnTCF1 and control cell lines were
cultured in 96-well plates in medium with or without dox-
ycycline. After 48 hours, absorbance of solubilized MTT
formazan crystals was measured on a microplatereader
(Labsystems Multiscan® MCC/340) at 540 nm. Experi-
ments were done in quaduplicates.
5'end rapid amplification of cDNA ends
5'-end RACE was performed using the Marathon-Ready™
colon adenocarcinoma cDNA library (Clontech) accord-
ing to the manufacturers recommendations. 5'-end RACE
products were generated using an antisense CLU gene spe-
cific 5'-RACE primer complementary to part of CLU exon
3: 5'- GGCATCCTCTTTCTTCTTCTTGGCTTC-3'. The Mar-
athon RACE PCR reaction was performed with Advantage
2 Polymerase Mix (50×) (Clontech). PCR products were
gel purified using the QIAquick Gel Extraction Kit (Qia-
gen), and cloned using the TOPO TA Cloning® Kit for
Sequencing (Invitrogen) according to the manufacturers
instructions. Cloned products from three colonies were
sequenced using Expand High Fidelity PCR System
(Roche Applied Science) and BigDye Terminator Kit
(Applied Biosystems) with an ABI 3100 Genetic Analyzer
(Applied Biosystems). The following plasmid specific
internal primers were used for sequencing; 5'-TAATAC-
GACTCACTATAGGG-3' (sense) and 5'-CAG-
GAAACAGCTATGAC-3' (reverse)
Western blotting
Whole cell extracts were prepared; pelleted cells were lysed
on ice in a lysis buffer containing 50 mM Tris, pH 7.5, 150
mM NaCl, 1% NP-40, 0.5% deoxycholic acid supple-
mented with protease inhibitor cocktail (Roche Applied
Science). Analysis of CLU levels in the culture medium
was done by acetone precipitation of the proteins in the
culture medium, after which the pellet was resuspended
in lysis buffer. Protein concentrations were determined byJournal of Molecular Signaling 2007, 2:6 http://www.jmolecularsignaling.com/content/2/1/6
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the Bradford assay. Samples were boiled 3 min in loading
buffer (350 mM Tris HCL, 30% glycerol, 0.1% SDS, 600
mM DTT, 0.012% W/V bromophenol blue) prior to load-
ing an equal amount of protein (20 μg cell extract, 40 μg
from medium) on each lane on precast NuPAGE 12% Bis-
Tris Gel (Invitrogen). Electrophoresis and blotting onto
polyvinylidene fluoride (PVDF) membrane were per-
formed according to standard minigel procedures for the
Novex XCell II Mini-Cell system. All-Blue prestained
standards (Bio-Rad) were used as molecular weight mark-
ers. After blocking with 3% skimmed milk, membrane
was incubated with primary antibodies; mouse mono-
clonal anti-CLU (1:400; clone 41D; Upstate, Charlottes-
ville, VA, USA), mouse monoclonal anti-c-Myc (1:100;
clone 9E10; Santa Cruz Biotechnology, Santa Cruz, CA,
USA), mouse monoclonal anti-TCF-1 (1 μg/ml; clone
7H3; Upstate), and mouse monoclonal anti-TCF-4 (1 μg/
ml; clone 6H5-2; Upstate). Final protein detection used
the secondary HRP-conjugated polyclonal goat anti-
mouse antibody (1:2500; DakoCytomation) in combina-
tion with ECL Plus reagent (Amersham Biosciences). As
loading control, parallel immunoblotting using an anti-β-
actin mouse monoclonal antibody (0.05 μg/ml; clone AC-
15; Sigma-Aldrich) was performed.
Immunofluorescence
For immunofluorescence analysis, cells were cultured on
glass coverslips. Cells were washed with PBS, fixed with
4% paraformaldehyde for 10 min at RT after which fixa-
tion was quenched by incubating in 0.1 M glycine-PBS
solution for 5 min. Cells were permeabilized for 5 min
with 0.1% Triton X-100 in PBS, washed with PBS, and
blocked with 1% BSA in PBS for 45 min at 37°C. After
washing with PBS, cells were incubated with primary anti-
bodies, mouse monoclonal anti-CLU (1:400; clone 41D;
Upstate) and mouse monoclonal anti-β-catenin (1:200;
BD Transduction Laboratories), followed by another wash
with PBS and then incubated with secondary antibody,
AlexaFlour 546 goat anti-mouse IgG1 (1:400; Molecular
Probes Inc.), for 1 h at 37°C. After being washed with PBS,
nuclei was stained using DAPI (4,6-diamidino-2-phe-
nylindole) (Sigma-Aldrich Denmark A/S, Copenhagen,
DK), and cells were mounted on microscope slides and
images were captured using a CCD camera (Quantix, Pho-
tometrics, Tucson, AZ, USA) mounted on a Leica DMRXA
epifluorescence microscope (Leica, Wetzlar, Germany)
with appropriate filters and operated via SmartCapture
software (Digital Scientific, Cambridge, UK).
Real time RT-PCR
Quantitative real time RT-PCR was performed on an ABI
PRISM® 7000 Sequence Detection System (Applied Bio-
systems, Foster City, CA, USA) using the relevant (TaqMan
or SYBR Green) Master Mix (Applied Biosystems). For
normalization, the gene Ubiquitin C (UBC) was used
using primer sequences previously published[34]. Total
RNA was purified using the GenElute™ Mammalian total
RNA miniprep kit (Sigma-Aldrich), including on-column
DNase digestion (Qiagen). RNA integrity was evaluated
by Bioanalyzer analysis using nano chips (Agilent Tech-
nologies). cDNA was generated using the Superscript™
cDNA synthesis kit (Invitrogen) with random nonamer
primers and RNAse inhibitor (Ambion, Austin, TX, USA).
The individual CLU mRNA variants were quantified using
variant specific primer/probe sets previously
reported[12]. Each measurement was performed in tripli-
cate, and no-template controls were included for each
assay. Relative expression values were obtained using a
four-point 10-fold dilution curve. The dilution curve was
created using a cDNA pool containing 2 μl of each of the
test cDNAs.
Sequencing of the genomic CLU locus
The integrity of the genomic CLU locus was analyzed by
bi-directional sequencing using the BigDye Terminator
Kit (Applied Biosystems) and the ABI 3100 genetic ana-
lyzer (Applied Biosystems). Fragments representing each
exon and the adjacent intron-exon boundaries were gen-
erated by PCR. Primer details of the sense and antisense
primers have been published elsewhere[12]. Sequencing
covered all 11 exons (Fig. 5A,B; 1a, 1b, 1c, and 2–9).
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Basal CLU expression in various prostate and colon carcinoma cell 
lines. Real time RT-PCR was used to measure basal CLU expression levels 
of three CLU mRNA variants in various prostate and colon carcinoma cell 
lines. Expression levels were normalized to the Ubiquitin C (UBC) tran-
script. CLU34 levels varied highly across the entire panel of cell lines, 
whereas CLU35 and CLU36 were consistently expressed at very low levels, 
in some samples below the limits of detection by the real time RT-PCR 
assay.
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